Careers  |  Sign In  |  Register

Latest in Oncology

Interim results from the preliminary analysis of the JAVELIN-Renal 101 trial suggest that adding immunotherapy to a targeted agent appears to significantly improve progression-free survival (PFS) when compared with a targeted agent alone in the first-line treatment of advanced renal cell carcinoma...
Researchers at the Technion - Israel Institute of Technology reduced cancer tumor size in mice by activating the brain’s reward system.
New guidelines urge conservative approach to PSA prostate cancer screening.